Highlights

Alopecia areata is a chronic autoimmune disease characterized by rapid hair loss without scarring. Hair loss usually occurs on the head and beard area, but can occur on any part of the body.

The most common type of alopecia areata is patchy (localized) alopecia areata: round bald spots with complete hair loss. The most severe types of alopecia areata result in complete hair loss on the head (alopecia totalis) or the entire body (alopecia universalis).

Alopecia areata occurs more frequently in persons under the age of 40 (up to 80% of patients), equally in men and women, and in half of the cases it develops before the age of 20.

Alopecia areata occurs in 0.1%–0.2% of the general population.

The cause of alopecia areata is unknown. It is probably due to a multifactorial genetic predisposition triggered by environmental factors. An autoimmune inflammatory process leads to destruction of the immune privilege of the hair follicle and subsequent attacks on previously healthy hair follicles. Since in alopecia areata, which is not a scarring disease, the hair follicle retains the ability to regenerate and continue its development cycle and its stem cells are usually not destroyed, hair loss followed by alopecia areata is positioned as a reversible condition in principle.

The existing pharmacological armamentarium to combat baldness due to alopecia areata is represented by the following drugs: topical corticosteroids (triamcinolone, betamethasone, clobetasol, mometasone, fluocinolone), topical minoxidil, topical tretinoin, topical anthralin (dithranol), topical immunotherapy (diphenylcyclopropenone [DPCP], squaric acid dibutylester [SADBE], systemic immunosuppressants (azathioprine, cyclosporine, methotrexate).

Despite the relatively wide variety of proposed pharmacological interventions for the treatment of alopecia areata, current approaches cannot be called unequivocally effective. This is why pharmaceutical companies continue to develop new medications against alopecia areata.

 

JAK Inhibitors

The pathogenesis of alopecia areata involves genetic [1] and immune factors. [2] [3] The proliferation and activation of autoreactive CD8+ T cells attacking hair follicles is driven by cytokines including interferon gamma (IFN-γ) and interleukin-15 (IL-15). [4] Since the latter are dependent on the JAK–STAT signaling pathway, inhibition of Janus kinases (JAKs) can be an effective treatment for alopecia areata. [5] JAK inhibitors have previously been shown to reverse hair loss in patients with alopecia areata. [3] [6] [7]

In general, JAK inhibitors have long and repeatedly proven their worth in the treatment of alopecia areata. This is evidenced by the positive results of a number of clinical trials and numerous individual cases of off-label use of this class of drugs.

It should be understood that the beneficial effect of JAK-inhibition, manifested by the recovery of hair growth, persists until the treatment is discontinued: after withdrawal of the drug, alopecia areata recurs in most cases. At the same time, its course may worsen, when the disease progresses more severely, resulting in more significant alopecia areata than before the start of treatment. It is unknown whether the rebound effect is true one (secondary to an increase in disease activity), a consequence of telogen effluvium (JAK inhibitors drive hair follicles into the anagen phase), or a consequence of quorum sensing effect at the organ level.

The question with the balance of efficacy and safety in case of long-term multi-year use of JAK inhibitors remains open to the end: their direct interference with the body’s immune system carries certain risks of developing serious adverse events, including infectious diseases (upper respiratory tract infections, urinary tract infections, tuberculosis, herpes zoster, herpes simplex), malignancies (lymphoma), major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke), thrombosis, gastrointestinal perforation.

  • These risks of serious adverse events remain, however, very low, based on the results of the long-term use of JAK inhibitors in the treatment of other diseases, such as rheumatoid arthritis, psoriatic arthritis, polycythemia vera, ulcerative colitis. [8] [9] [10] [11] [12] [13]

 

Baricitinib

In mid-June 2022, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved Olumiant (baricitinib) for the treatment of severe alopecia areata in adults.

Baricitinib (LY3009104, INCB28050) is an oral small-molecule selective reversible inhibitor of Janus kinase 1 and 2 (JAK1/JAK2).

Baricinitib was developed by Incyte, which licensed it to Eli Lilly in December 2009. It was paid $90 million up front and promised up to $665 million as the project developed, plus royalties from sales of the finished drug.

Olumiant debuted in February 2017 to treat moderate-to-severe rheumatoid arthritis, then expanded its indications to include treatment for atopic dermatitis (eczema). A combination of Olumiant and Veklury (remdesivir) is used to treat COVID-19 infection in hospitalized adults and children requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

The BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) phase 2/3 (randomized, double-blind, placebo-controlled, multicenter, international) clinical trials, identical in design, enrolled adult patients (n=1200) with severe or very severe alopecia areata (SALT score ≥ 50).

  • The severity of the disease was assessed by the Severity of Alopecia Tool (SALT), with a final score ranging from 0 to 100, where 0 means no hair loss and 100 means complete hair loss.

Daily 36-week administration of baricitinib at a dose of 2 mg or 4 mg resulted in a statistically significant difference with the placebo group in the proportion of patients demonstrating hair growth on at least 80% of the scalp (SALT score ≤ 20).

6%, 23%, and 39% of patients in the placebo, 2-mg baricitinib, and 4-mg baricitinib groups, respectively, reached the indicated score in BRAVE-AA1. In BRAVE-AA2, this rate was recorded for 3%, 19%, and 36% of patients.

At least 90% hair regrowth (SALT ≤ 10) was reported in 4%, 13%, 28%, and 1%, 12%, 26% of subjects, respectively.

baricitinib alopecia areata results 01 - Alopecia Areata Treatment: What Future Holds
Efficacy of treatment of baldness due to alopecia areata with Olumiant (baricitinib) administered daily for 9 months. In the BRAVE-AA1 ( NCT03570749) clinical trial, patients A, B, C, and D took baricitinib 4 mg each, and patients E and F took 2 mg each. Image: N Engl J Med. 2022 May 5;386(18):1687-1699.
baricitinib alopecia areata results 03 - Alopecia Areata Treatment: What Future Holds
A case of an 18-year-old Spanish female patient treated for hair loss due to alopecia areata with Olumiant (baricitinib). Image: Sergio Vañó/El país.
baricitinib alopecia areata results 02 - Alopecia Areata Treatment: What Future Holds
A case of a 60-year-old female patient with alopecia universalis, who was prescribed Olumiant (baricitinib) daily for 8 months, at 2 mg for the first 4 months, then 4 mg. Treatment of hair loss resulted in almost complete regrowth of hair including on the eyebrows and eyelashes. Image: JAAD Case Rep. 2019 Oct 22;5(10):892-894.
baricitinib alopecia areata results 04 - Alopecia Areata Treatment: What Future Holds
A case of a 27-year-old Japanese female patient with alopecia areata. Results of baldness treatment after 4 and 8 weeks of Olumiant (baricitinib) prescription at 4 mg daily. Image: Ann Rheum Dis. 2020 May;79(5):674-675.

 

Tofacitinib

Oral Xeljanz (tofacitinib), a Pfizer-developed Janus kinase 1, 2, and 3 (JAK1/JAK2/JAK3) inhibitor, is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis.

Tofacitinib has long been successfully used off-label in the treatment of alopecia areata. However, Pfizer is not specifically evaluating tofacitinib in alopecia areata, believing that it is more appropriate to develop other drug compounds that may be more effective and safer against this condition.

tofacitinib alopecia areata results 18 - Alopecia Areata Treatment: What Future Holds
A case of a 16-year-old female patient with alopecia areata that started when she was 3 years old. Results of a 2-year hair loss treatment with Xeljanz (tofacitinib) at 10 mg every morning and 5 mg every evening. Image: Pediatr Dermatol. 2022 Jan;39(1):31-34.
tofacitinib alopecia areata results 04 - Alopecia Areata Treatment: What Future Holds
A case of a 30-year-old Turkish female patient with alopecia universalis of 4 years duration. Results of hair loss treatment with Xeljanz(tofacitinib) at 10 mg daily after 3, 6, and 12 months. Image: J Cosmet Dermatol. 2021 Sep;20(9):3026-3033.
tofacitinib alopecia areata results 05 - Alopecia Areata Treatment: What Future Holds
A case of a 32-year-old Turkish female patient with alopecia universalis of 18 years duration. Results of hair loss treatment with Xeljanz (tofacitinib) at 10 mg daily after 4, 8, and 12 months. Image: J Cosmet Dermatol. 2021 Sep;20(9):3026-3033.
tofacitinib alopecia areata results 06 - Alopecia Areata Treatment: What Future Holds
A case of a 29-year-old Chinese female patient with 10 years of alopecia areata. Results of hair loss treatment with Xeljanz (tofacitinib), which was administered 5 mg twice daily for 7 months and then 5 mg once daily, after 2 months of therapy (C, D) and after 8 months (E, F). Image: Front Immunol. 2021 Apr 14;12:654376.
tofacitinib alopecia areata results 09 - Alopecia Areata Treatment: What Future Holds
A case of a 51-year-old Korean female patient with alopecia areata. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 3, 5, and 7 months of therapy. Image: J Dermatol. 2019 Aug;46(8):724-730.
tofacitinib alopecia areata results 33 - Alopecia Areata Treatment: What Future Holds
A case of a female patient with alopecia universalis. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 3, 6, and 9 months of therapy. Image: Dermatol Ther. 2019 May;32(3):e12844.
tofacitinib alopecia areata results 29 scaled - Alopecia Areata Treatment: What Future Holds
A case of a 29-year-old Korean patient with alopecia areata that started a year ago. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 2 and 5 months of therapy. Image: J Dermatol. 2019 Apr;46(4):e139-e140.
tofacitinib alopecia areata results 30 - Alopecia Areata Treatment: What Future Holds
A case of a 4-year-old patient with alopecia totalis that started a year ago. Results of hair loss treatment with Xeljanz (tofacitinib) at 2.5 mg daily after 6 and 12 months of therapy. Image: J Am Acad Dermatol. 2019 Apr;80(4):1164-1166.
tofacitinib alopecia areata results 31 - Alopecia Areata Treatment: What Future Holds
A case of an adolescent patient with alopecia areata. Results of a 2-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily. Image: JAAD Case Rep. 2019 Apr; 5(4): 365-367.
tofacitinib alopecia areata results 32 - Alopecia Areata Treatment: What Future Holds
A case of a 44-year-old female patient with 5 years of alopecia areata. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 4 months of therapy and 6 weeks after discontinuation of treatment (hair loss significantly worsened compared to the original baldness). Image: J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e156-e157.
tofacitinib alopecia areata results 24 - Alopecia Areata Treatment: What Future Holds
A case of an 8-year-old female patient whose alopecia universalis started when she was 6 years old. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 6 and 9 months of therapy. Image: J Am Acad Dermatol. 2019 Feb;80(2):568-570.
tofacitinib alopecia areata results 10 - Alopecia Areata Treatment: What Future Holds
A case of a female patient with alopecia universalis. Results of a 3-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily. Image: Dermatology. 2019;235(2):130-136.
tofacitinib alopecia areata results 14 scaled - Alopecia Areata Treatment: What Future Holds
A case of a 17-year-old patient with alopecia areata lasting 10 years and progressing to alopecia universalis. A tattoo imitating a shaved head was placed on the scalp. Results of hair loss treatment with Xeljanz (tofacitinib) at 10 mg daily after 4 and 6 months of therapy, after 8 months (new alopecia foci), after 9.5 months (spread of alopecia foci despite increasing tofacitinib dose to 15 mg daily). Image: JAAD Case Rep. 2018 Aug; 4(7): 733-736.
tofacitinib alopecia areata results 16 - Alopecia Areata Treatment: What Future Holds
A case of a 17-year-old patient with alopecia areata that began at age 13. Results of a 5-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily. Image: J Cutan Med Surg. Jul/Aug 2018;22(4):439-442.
tofacitinib alopecia areata results 17 - Alopecia Areata Treatment: What Future Holds
A case of a 40-year-old patient with 16 years history of alopecia areata. Results of hair loss treatment with Xeljanz (tofacitinib) administered for several months (at 5 mg once daily for the first month, then 5 mg twice daily). Image: J Cutan Med Surg. Jul/Aug 2018;22(4):439-442.
tofacitinib alopecia areata results 11 - Alopecia Areata Treatment: What Future Holds
Dynamics of hair growth during alopecia areata treatment with Xeljanz (tofacitinib), which was administered twice daily at 5 mg (or 10 mg if the patient did not respond). After therapy was discontinued, hair loss tended to return. Image: J Invest Dermatol. 2018 Jul;138(7):1539-1545.
tofacitinib alopecia areata results 13 - Alopecia Areata Treatment: What Future Holds
A case of a female patient with alopecia areata. Results of an 11-month hair loss treatment with Xeljanz (tofacitinib) administered at 10 mg daily for the first 2 months, then at 15 mg for 7 months, then at 22 mg. Image: J Drugs Dermatol. 2018 Jul 1;17(7):800-803.
tofacitinib alopecia areata results 15 - Alopecia Areata Treatment: What Future Holds
A case of a 22-year-old patient with alopecia areata that began in childhood and progressed to alopecia universalis. Results of a 10-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily. Image: JAAD Case Rep. 2018 Jul; 4(6): 515-517.
tofacitinib alopecia areata results 27 - Alopecia Areata Treatment: What Future Holds
Results of alopecia areata treatment with Xeljanz (tofacitinib), which was administered at 5 mg twice daily for the first month and then at 10 mg twice daily, after 4 months of therapy (A and B), after 2 and 3 months (C). Image: Int J Trichology. 2018 May-Jun; 10(3): 103-107.
tofacitinib alopecia areata results 28 - Alopecia Areata Treatment: What Future Holds
Results of alopecia areata treatment with Xeljanz (tofacitinib), which was administered at 5 mg twice daily for the first month and then 10 mg twice daily, after 3 and 4 months of therapy. Image: Int J Trichology. 2018 May-Jun; 10(3): 103-107.
tofacitinib alopecia areata results 12 - Alopecia Areata Treatment: What Future Holds
Results of a 3-month treatment of alopecia areata with Xeljanz (tofacitinib) at 5 mg twice daily. Image: JAMA Dermatol. 2017 Jun; 153(6): 600-602.
tofacitinib alopecia areata results 21 - Alopecia Areata Treatment: What Future Holds
A case of a 23-year-old female patient whose alopecia areata began at age 14 and progressed to alopecia universalis at age 19. Results of hair loss treatment with Xeljanz (tofacitinib), which was administered at 5 mg twice daily for the first 2 months and then 10 mg in the morning and then 5 mg in the evening, after 2 months of therapy (A and B), after 3 months (C), after 4.5 months (D and E), after 6 months (F and G). Image: Acta Dermatovenerol Alp Pannonica Adriat. 2017 Jun;26(2):47-49.
tofacitinib alopecia areata results 01 - Alopecia Areata Treatment: What Future Holds
A case of a 28-year-old Korean female patient whose alopecia areata began in her 20s and then progressed to alopecia universalis. The hair loss was treated with Xeljanz (tofacitinib) at 5 mg twice daily for 8 months. Results after 2 weeks of treatment (b), almost complete hair regrowth after 6 weeks (c), complete hair regrowth after 8 months (d). Image: Singapore Med J. 2017 May; 58(5): 279-280.
tofacitinib alopecia areata results 19 - Alopecia Areata Treatment: What Future Holds
A case of a 16-year-old female patient with alopecia universalis beginning at the age of 4. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 1, 4, 12, and 18 months of therapy. Image: J Am Acad Dermatol. 2017 Apr;76(4):754-755.
tofacitinib alopecia areata results 20 - Alopecia Areata Treatment: What Future Holds
A case of a 20-year-old German female patient with alopecia universalis developed 2 years ago. Results of hair loss treatment with Xeljanz (tofacitinib), which was initially administered at 15 mg daily, then the dose was reduced to 10 mg, after 3 and 7 months of therapy. Image: Acta Derm Venereol. 2017 Feb 8;97(2):283-284.
tofacitinib alopecia areata results 07 - Alopecia Areata Treatment: What Future Holds
Results of alopecia areata treatment with Xeljanz (tofacitinib). Image: J Am Acad Dermatol. 2017 Jan;76(1):22-28.
tofacitinib alopecia areata results 08 - Alopecia Areata Treatment: What Future Holds
A case of a 15-year-old female patient with alopecia areata. Results of hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily after 2 and 5 months of therapy. Image: J Am Acad Dermatol. 2017 Jan;76(1):29-32.
tofacitinib alopecia areata results 22 - Alopecia Areata Treatment: What Future Holds
A case of a 38-year-old Brazilian patient with 10 years of alopecia universalis. Results of a 9-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily. Image: Ann Intern Med. 2016 Nov 15;165(10):750-751.
tofacitinib alopecia areata results 23 - Alopecia Areata Treatment: What Future Holds
A case of a 20-year-old Brazilian female patient with 10 years of alopecia universalis. Results of a 9-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily. Image: Ann Intern Med. 2016 Nov 15;165(10):750-751.

 

Ruxolitinib

Oral Jakafi/Jakavi (ruxolitinib), a Janus kinase 1 and 2 (JAK1/JAK2) inhibitor developed by Incyte and Novartis, is approved for the treatment of myelofibrosis (primary and secondary due to polycythemia vera or essential thrombocythemia), polycythemia vera, graft-versus-host disease.

Ruxolitinib has long been successfully used off-label in the treatment of alopecia areata. However, neither Incyte nor Novartis are conducting a specific clinical trial of ruxolitinib for alopecia areata because the former already has baricitinib approved for this indication, while the focus of the latter is shifted to more profitable areas.

ruxolitinib alopecia areata results 05 - Alopecia Areata Treatment: What Future Holds
A case of a patient with alopecia universalis. Results of a 6-month hair loss treatment with Jakafi/Jakavi (ruxolitinib) at 20 mg twice daily. Image: Dermatology. 2019;235(2):130-136.
ruxolitinib alopecia areata results 09 - Alopecia Areata Treatment: What Future Holds
A case of a 14-year-old female patient with alopecia universalis. A 4-month hair loss treatment with Xeljanz (tofacitinib) at 5 mg twice daily for the first 2 months and 10 mg twice daily thereafter failed (A), whereas a subsequent 7-month hair loss treatment with Jakafi/Jakavi (ruxolitinib) at 10 mg twice daily was effective (B). Image: J Am Acad Dermatol. 2019 Feb;80(2):566-568.
ruxolitinib alopecia areata results 10 - Alopecia Areata Treatment: What Future Holds
A case of a 40-year-old patient with alopecia areata. Results of a 10-month hair loss treatment with Jakafi/Jakavi (ruxolitinib) administered initially at 5 mg twice daily, then at 10 mg twice daily. Image: JAMA Dermatol. 2018 Nov 1; 154(11): 1357-1358.
ruxolitinib alopecia areata results 06 - Alopecia Areata Treatment: What Future Holds
Regrowth of beard hair in a 33-year-old ultra-Orthodox Jew man with alopecia universalis after 4 months of hair loss treatment with Jakafi/Jakavi (ruxolitinib) at 2 mg twice daily. Image: Skin Appendage Disord. 2018 Apr; 4(2): 122-124.
ruxolitinib alopecia areata results 07 - Alopecia Areata Treatment: What Future Holds
A case of a 59-year-old female patient with a 10-year history of alopecia areata and 2 years of ongoing alopecia totalis. Results of hair loss treatment with Jakafi/Jakavi (ruxolitinib) for 1 year. Ruxolitinib was given at 5 mg twice daily for the first 2 weeks, then gradually increased to 15 mg twice daily over 3 months. Image: Int J Dermatol. 2017 Aug; 56(8): 833-835.
ruxolitinib alopecia areata results 08 - Alopecia Areata Treatment: What Future Holds
A case of a 45-year-old female patient with alopecia areata. Results of hair loss treatment with Jakafi/Jakavi (ruxolitinib) for 1 year. Ruxolitinib was administered at 5 mg twice daily for the first month, then the dose was gradually increased to 15 mg twice daily over 3 months. Image: Int J Dermatol. 2017 Aug; 56(8): 833-835.
ruxolitinib alopecia areata results 03 - Alopecia Areata Treatment: What Future Holds
A case of a patient with alopecia areata. Results of hair loss treatment with Jakafi/Jakavi (ruxolitinib) at 20 mg twice daily after 3 and 4 months of therapy. Image: Nat Med. 2014 Sep; 20(9): 1043-1049.
ruxolitinib alopecia areata results 04 - Alopecia Areata Treatment: What Future Holds
A case of a female patient with alopecia areata. Results of hair loss treatment with Jakafi/Jakavi (ruxolitinib) at 20 mg twice daily after 3 and 5 months of therapy. Image: Nat Med. 2014 Sep; 20(9): 1043-1049.

 

Deuruxolitinib

In the first half of 2023, Concert Pharmaceuticals plans to submit to regulators the New Drug Application (NDA) for oral deuruxolitinib (CTP-543), which is ruxolitinib whose chemistry is altered by deuterium.

The suggested brand name for deuruxolitinib is Leqselvi or Tidasviq.

  • Selective inclusion of deuterium instead of hydrogen in the chemical structure of the drug leads to changes in its therapeutic properties, including increased half-life, improved oral bioavailability, optimized metabolic profile, and improved safety.

In the THRIVE-AA1 (NCT04518995) phase 3 (randomized, double-blind, placebo-controlled, multicenter, international) clinical trial among adult patients (n=706) with moderate-to-severe alopecia areata, administration of deuruxolitinib twice daily in a dose of 8 mg or 12 mg for 24 weeks resulted in a SALT score ≤ 20 for 30% and 42% of subjects, respectively — versus 0.8% in the placebo group (p<0,0001).

In the THRIVE-AA2 (NCT04797650) phase 3 clinical trial, similar in design, which enrolled adult patients (n=517) with moderate-to-severe alopecia areata, deuruxolitinib administered twice daily at a dose of 8 or 12 mg for 24 weeks yielded a SALT score ≤ 20 among 33% and 38% of patients — versus 0.8% in controls (p<0.0001).

deuruxolitinib alopecia areata results 03 - Alopecia Areata Treatment: What Future Holds
Results of deuruxolitinib administered at 8 mg twice daily after 3 and 6 months of hair loss treatment for alopecia areata.
deuruxolitinib alopecia areata results 04 - Alopecia Areata Treatment: What Future Holds
Results of deuruxolitinib administered at 8 mg twice daily after 3 and 6 months of hair loss treatment for alopecia areata.

 

Ivarmacitinib

China’s Jiangsu Hengrui Pharmaceuticals is testing ivarmacitinib (SHR0302), an oral Janus kinase 1 (JAK1) inhibitor, for the treatment of several autoimmune diseases including alopecia areata.

China’s Reistone Biopharma, which has licensed ivarmacitinib from Hengrui, has successfully completed the CRYSTAL2 (NCT04346316) phase 2 (randomized, double-blind, placebo-controlled, multicenter, international) clinical trial among adult patients (n=94) with moderate-to-severe alopecia areata.

We tell you what others don’t tell you.

Sign up for the BioPharma Media’s newsletter.

BioPharma Media

 

Jaktinib

China’s Suzhou Zelgen Biopharmaceuticals is rolling out jaktinib, an oral Janus kinase 1, 2, and 3 (JAK1/JAK2/JAK3) inhibitor, to treat a variety of autoimmune diseases including alopecia areata.

Several clinical trials are underway to do this: 24-week NCT04034134 phase 2 and 24-week NCT05051761 phase 3 with an additional 24-week NCT05255237 phase 3.

 

Ritlecitinib

Pfizer is developing oral ritlecitinib (PF-06651600), which, in addition to inhibiting Janus kinase 3 (JAK3), inhibits the family of non-receptor protein-tyrosine kinases (TEC), leading to suppression of cytolytic function of CD8+ T cells and natural killer (NK) cells.

The ALLEGRO (NCT03732807) phase 2b/3 (randomized, double-blind, placebo-controlled, multicenter, international) clinical trial enrolled patients (n=718) aged 12 years and older with moderate-to-severe alopecia areata. Daily administration of ritlecitinib at 30 mg or 50 mg resulted in a statistically significant difference with the placebo group in achieving a SALT score ≤ 20 after 24 weeks of treatment. Thus, 23% and 14% of patients reached the specified primary efficacy endpoint — versus 2% in the placebo group.

The long-term ALLEGRO-LT (NCT04006457) phase 3 clinical trial is ongoing, including participants of NCT02974868 and NCT03732807, which evaluates the efficacy and safety of daily use of ritlecitinib in a 50 mg dose to treat alopecia areata for 3 years.

 

Anacell

Korea’s D.Nature offers Anacell, also known as CMX and DN-001, an over-the-counter topical cosmeceutical that contains the plant-derived sesquiterpene lactone brevilin A derived from Centipeda minima. Brevilin A is a Janus kinase 3 (JAK3) inhibitor and activator of Wnt/beta-catenin signaling pathway responsible, among others, for neogenesis of hair follicles and anagen phase initiation. [1] [2] [3] [4]

D.Nature is working on an improved version of Anacell.

It should be understood that any topical formulations of JAK inhibitors are inferior in efficacy to systemic JAK inhibitors, according to a number of clinical trials. [5] [6] [7]

 

Etrasimod

Pfizer is studying etrasimod (APD334), an oral agonist of sphingosine-1-phosphate receptors 1, 4, and 5 (S1PR1/S1PR4/S1PR5).

The immunomodulatory mechanism of action of etrasimod is due to internalization of sphingosine-1-phosphate receptors (S1PRs) with their subsequent degradation (functional antagonism) in the ubiquitin–proteasome metabolic pathway. This leads to inhibition of migration of a certain subtype of activated lymphocytes (T helpers CD4+ CCR7+ and T killers CD8+ CCR7+) from the lymphoid tissue to the sites of inflammation. The integrity of immunological surveillance for infections and tumors is preserved because S1P signaling does not affect a subset of lymphocytes that do not migrate through the lymphoid tissue.

Etrasimod-like S1PRs agonists such as Gilenya (fingolimod), Mayzent (siponimod), Zeposia (ozanimod), and Ponvory (ponesimod), are used in the treatment of relapsing forms of multiple sclerosis and inflammatory bowel disease (ulcerative colitis).

Etrasimod, obtained from Arena Pharmaceuticals, purchased in March 2022 for nearly $6.7 billion, is in a 24-week NCT04556734 phase 2 (randomized, double-blind, placebo-controlled, multicenter, international) clinical trial among adult patients (n=78) with moderate-to-severe alopecia areata who receive daily etrasimod at a dose of 2 mg or 3 mg.


 

Coacillium

Switzerland’s Legacy Healthcare came up with Coacillium (LH-8), also known as Cellium, CG210 and CG428, a proprietary blend of water-alcoholic extracts from onion bulb (Allium cepa), lemon fruit (Citrus limon), cocoa seed (Theobroma cacao), and guarana seed (Paullinia cupana).

In autoimmune diseases, this cosmeceutical combination of flavonoids and polyphenols has a pleiotropic effect on the skin when applied topically. This has been confirmed by a number of clinical trials treating androgenic alopecia in men and women. [1] [2] [3] A clinical trial of treatment of chemotherapy-induced alopecia has been successfully completed. [4]

Coacillium is believed to normalize cellular resistance to apoptosis by restoring the number of cells expressing the antiapoptotic protein Bcl-2, which acts during the catagen phase (resting stage in the hair development cycle), thereby prolonging the anagen phase (growth stage) and cell survival. Coacillium has an anti-inflammatory effect due to a significant increase in the number of Langerhans cells and mast cells in the perifollicular area, which prevents miniaturization of follicles and fibrosis. Coacillium promotes collagen content and remodeling around the hair follicle. [5] [6]

We tell you what others don’t tell you.

Sign up for the BioPharma Media’s newsletter.

BioPharma Media

Coacillium, which is an over-the-counter hair care product, is freely available for purchase. The lotion is marketed under different brands with partner support from Galderma, Abbott Laboratories, Sanofi, DKSH, and other pharmaceutical manufacturers.

The ongoing 24-week RAAINBOW (NCT03240627) phase 2/3 (randomized, double-blind, placebo-controlled, multicenter, international) clinical trial enrolled patients (n=106) aged 2–18 years with moderate-to-severe pedatric alopecia areata lasting up to 3 years. Subjects were administered a topical 21% Coacillium solution twice daily.

 

Rosnilimab

AnaptysBio believes it can do well with the treatment of alopecia areata by targeting a key regulator of the immune response that suppresses T cell inflammatory activity. We are talking about programmed cell death protein 1 (PD-1).

There are many PD-1 and its ligand, PD-L1, blockers on the market, such as Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab), which by binding to PD-(L)1 and inhibiting its activity, effectively remove the brakes from the immune system allowing it to actively counteract cancer.

AnaptysBio has taken a different, opposite path. The humanized monoclonal antibody rosnilimab (ANB030) binds to PD-1, but instead of acting antagonistically on this receptor expressed on immune cells, has an agonist effect, thereby suppressing T cell inflammatory activity, which is desirable in alopecia areata as a T cell–mediated autoimmune disease. Genetic mutations in the PD-(L)1 signaling pathway that result in a lack of its functional expression are thought to be associated with increased susceptibility to inflammatory diseases, and therefore it makes sense to enhance PD-1 function. [1] [2] [3] [4] [5]

The ongoing 24-week AZURE (NCT05205070) phase 2 (randomized, double-blind, placebo-controlled, multicenter) clinical trial enrolling adult patients (n=45) with moderate-to-severe alopecia areata is testing monthly subcutaneous injections of rosnilimab.

 

EQ101

Equillium is trying its hand with EQ101 (BNZ-1) from Bioniz Therapeutics, which was acquired in February 2022.

EQ101 is a pegylated peptide inhibitor of interleukin 2 (IL-2), interleukin 9 (IL-9), and interleukin 15 (IL-15), cytokines that control basic immune responses. EQ101 targets the common gamma chain signal receptor subunit for these cytokines. Administration of EQ101 results in pharmacodynamic effects associated with decreased levels of regulatory T cells (Treg), natural killer (NK) cells, and CD8+ central memory T cells (Tcm). Such action may be more effective and safer than Janus kinase (JAK) inhibition, which is not particularly selective due to partial inhibition of signaling of all six cytokines with the gamma chain.

A 12-week NCT03532958 phase 2 (randomized, double-blind, placebo-controlled) clinical trial is planned in adult patients (n=125) with moderate-to-severe alopecia areata who will receive weekly intravenous infusions of EQ101.

At one time, the University Hospital of Nice (France) tested exactly the opposite idea. They claimed that administration of low-dose recombinant interleukin 2 (IL-2) had a beneficial therapeutic effect on the course of alopecia areata. The theory was that a key role in the pathogenesis of the disease is played by impaired inhibitory function of Treg CD4+ CD25+, leading to a loss of immune privilege of hair follicles, and IL-2 administration can restore it by expanding the population of these immune cells. [1] [2] [3] [4] [5] [6]

In the NCT01840046 phase 1/2 (nonrandomized, open-label) clinical trial, adult patients (n=5) with severe alopecia alopecia resistant to prior systemic therapy received subcutaneous IL-2: 5 consecutive days of 1.5 million IU/day, followed by three 5-day courses of 3 million IU/day at weeks 3, 6 and 9. After 6 months, the median SALT score changed from 82 to 69.

In a subsequent phase 2 (randomized, open-label, placebo-controlled, multicenter) clinical trial among adult patients (n=43) with severe alopecia areata, administration of subcutaneous IL-2 in four cycles did not result in the desired treatment effect. After 12 months of follow-up, a 50% reduction in SALT score was observed for 14.3% of patients — versus 9.1% in the placebo group (p=0.66).

 

SP16

Serpin Pharma’s focus is on serpins, a family of proteins that are primarily serine protease inhibitors.

Serpin’s main and so far only medicinal asset is the drug candidate SP16, which is a short amino acid sequence derived from alpha-1 antitrypsin (AAT), a well-known serpin that plays a critical role in the inflammation cascade. The mechanism of action of SP16 is seen in the agonism of the low density lipoprotein receptor-related protein (LRP1), which, ubiquitously expressed in multiple tissues, plays a key role in intracellular signaling and endocytosis. LRP1 agonism is reflected by its potent anti-inflammatory and immunomodulatory actions. SP16, which is positioned as a first-in-class peptide master switch for inflammation, is being studied in the treatment of a wide range of inflammatory and autoimmune diseases including alopecia areata. [1] [2] [3] [4] [5]

close
BioPharma Media

We tell you what others don’t tell you.

Sign up for the BioPharma Media’s newsletter.

BioPharma Media is a fully independent and non-profit analytical service. That’s why we report on the pharma & biotech industry in a completely honest, objective, and unbiased way.

Read our privacy policy for more info.

Julia Mardi

BioPharma Media’s Scientific Editor.

Julia strives to recognize in advance in which direction the pharmaceutical industry is moving. Her professional interests include gene therapy, immune checkpoint inhibitors, molecular biology, and drug repurposing.

For more information about Julia and her contact data, see Our Team.

Timur Burkhanayev

BioPharma Media’s Data Analyst.

Timur mines and analyzes scientific and business data, providing meaningful insights. His professional interests include budgeting, forecasting, financial analyses, and data processing tools.

For more information about Timur and his contact data, see Our Team.

Leave a comment

Tell us what you think of what we posted. It is possible that you have comments, additions, or even remarks. BioPharma Media welcomes readers' feedback and criticism.

Please pay special attention that BioPharma Media enters into correspondence on any issues except those indicated in section 5 of the Terms of Use, which will never, under any circumstances, be responded to or answered.

Your email address will not be published.